Debanjan Ray, Synthekine CEO
Merck dives even further into cytokine research as deal spree continues
Merck’s new leadership hasn’t been shy about its desire to spend, agreeing to drop $11.5 billion on a new biotech and promising to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
